Basic parameters of thrombophilia in ocular Behçet disease with posterior segment involvement

British Journal of Ophthalmology

Volumn 93, Issue 10, 2009, Pages 1382-1386

  Citirik, M ^a,c   Haznedaroglu, I C ^b   Teberik, K ^a   Soykan, E ^a   Zilelioglu, O ^a  

^a Ankara Ulucanlar Eye Research Hospital   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; PROTEIN C; PROTEIN S;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; THROMBOPHILIA; UVEITIS;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; ANTITHROMBIN III; BEHCET SYNDROME; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN C; PROTEIN S; THROMBOPHILIA; UVEITIS, POSTERIOR; YOUNG ADULT;

EID: 70349974682     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.161018     Document Type: Article

References (40)

1. Verity DH, Wallace GR, Vaughan RW, et al. Behçet's disease: from Hippocrates to the third millennium. Br J Ophthalmol 2003;87:1175-1183
2. Dündar S, Ünal S, Sivri B, et al. Behçet's disease in Turkish population: analysis of 200 cases. In: Lehner T, Barnes C, eds. Recent advances in Behçet's disease. London: Royal Society of Medicine Services, 1986:219-221
3. Hazleman B. Rheumatic disorders of the eye and the various structures involved. Br J Rheumatol 1996;35:258-268 (Pubitemid 126719434)
4. Ozdal PC, Ortac S, Taskintuna I, et al. Posterior segment involvement in ocular Behçet's disease. Eur J Ophthalmol 2002;12:424-431 (Pubitemid 35428797)
5. Nussenblatt R, Whitcup SM, Palestine A. Behçet's disease. In: Nussenblatt R, Whitcup SM, Palestine A, eds. Uveitis. 2nd edn. St Louis: Mosby, 1996:334-353
6. Haznedaroglu IC, Celik I, Buyukasik Y, et al. Hemostasis, thrombosis and endothelium in Behçet's disease. Acta Haematol 1998;99:236-237 (Pubitemid 28230396)
7. Lee YJ, Kang SW, Yang JI, et al. Coagulation parameters and plasma total homocysteine levels in Behçet's disease. Thromb Res 2002;106:19-24. (Pubitemid 34879960)
8. Navarro S, Ricart JM, Medina P, et al. Activated protein C levels in Behçet's disease and risk of venous thrombosis. Br J Haematol 2004;126:550-556 (Pubitemid 39093098)
9. Corrigan JJ. Thrombotic disorders. In: Nelson textbook of pediatrics. 15th edn. Behrman RE, Kliegman RM, Arvin EM, et al, eds. Philadelphia: WB Saunders, Chapter 440, 1995:1665-1666
10. Mader R, Ziv M, Adawi M, et al. Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behçet's disease. J Rheumatol 1999;26:2404-2408 (Pubitemid 29528982)
11. Jensen R, Ens GE. Resistance to activated protein C: a major cause of inherited thrombophilia. Clin Lab Sci 1997;10:219-222
12. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-1080
13. Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 1987;103:234-235
14. Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol 1996;143:1257-1265 (Pubitemid 26178738)
15. Benezra D, Cohen E. Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol 1986;70:589-592 (Pubitemid 16038279)
16. Stübiger N, Zierhut M, Kötter I. Ocular manifestations in Behçet's disease. In: Zierhut M, Ohno S, eds. Immunology of Behçet's disease. Lisse: Swets & Zeitlinger, 2003:36-45.
17. Kosar A, Ozturk M, Haznedaroglu IC, et al. Haemostatic parameters in Behçet's disease: a reappraisal. Rheumatol Int 2002;22:9-15. (Pubitemid 34591708)
18. Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001;29:S48-51.
19. Lenk N, Ozet G, Alli N, et al. Protein C and protein S activities in Behçet's disease as risk factors of thrombosis. Int J Dermatol 1998;37:124-125 (Pubitemid 28194711)
20. Nalcaci M, Pekcelen Y. Antithrombin III, protein C and protein S plasma levels in patients with Behçet's disease. J Int Med Res 1998;26:206-208 (Pubitemid 28477157)
21. Guermazi S, Hamza M, Dellagi K. Protein S deficiency and antibodies to protein S in patients with Behçet's disease. Thromb Res 1997;86:197-204. (Pubitemid 27235103)
22. Espinosa G, Font J, Tassies D, et al. Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002;112:37-43. (Pubitemid 34113853)
23. Vinazzer H. Hereditary and acquired antithrombin deficiency. Semin Thromb Hemost 1999;25:257-263
24. Ozoran K, Dugun N, Gurler A, et al. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease. Scand J Rheumatol 1995;24:376-382 (Pubitemid 26046453)
25. Demirer S, Sengul N, Yerdel MA, et al. Haemostasis in patients with Behçet's disease. Eur J Vasc Endovasc Surg 2000;19:570-574
26. Sengul N, Demirer S, Yerdel MA, et al. Comparison of coagulation parameters for healthy subjects and Behçet disease patients with and without vascular involvement. World J Surg 2000;24:1584-1588 (Pubitemid 32047292)
27. Rodgers GM. Thrombosis and antithrombotic therapy. In: Lee GR, Foerster J, Lukens J, et al., eds Wintrobe's clinical haematology. 10th edn. Baltimore: Williams & Wilkins, 1999:1781-1818
28. Dahlback B. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation. Semin Thromb Hemost 1999;25:273-289 (Pubitemid 29357748)
29. Verity DH, Vaughan RW, Madanat W, et al. Factor V Leiden mutation is associated with ocular involvement in Behçet disease. Am J Ophthalmol 1999;128:352-356 (Pubitemid 29413233)
30. Kosar A, Haznedaroglu IC, Buyukasik Y, et al. Activated protein C resistance in Behçet's disease. Rheumatol Int 1998;17:249-250
31. Oner AF, Gurgey A, Gurler A, et al. Factor V Leiden mutation in patients with Behçet's disease. J Rheumatol 1998;25:496-498 (Pubitemid 28109352)
32. Batioǧlu F, Atmaca LS, Karabulut HG, et al. Factor V Leiden and prothrombin gene G20210A mutations in ocular Behçet disease. Acta Ophthalmol Scand 2003;81:283-285 (Pubitemid 36806268)
33. Gregg JP, Yamane AJ, Grody WW. Prevalence of factor V-Leiden mutation in four distinct American ethnic populations. Am J Med Genet 1997;73:334-336
34. Herrmann FH, Koesling M, Schoeder W, et al. Prevalence of factor V Leiden mutation in various populations. Genet Epidemiol 1997;14:403-411 (Pubitemid 27347251)
35. Pepe G, Rickards O, Vanegas OC, et al. Prevalence of factor V Leiden mutation in non-European populations. Thromb Haemost 1997;77:329-331 (Pubitemid 27084925)
36. Zivelin A, Griffin JH, Xu X, et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997;89:397-402. (Pubitemid 27051673)
37. Leiba M, Seligsohn U, Sidi Y, et al. Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease. Ann Rheum Dis 2004;63:1445-1449 (Pubitemid 39433949)
38. Ricart JM, Vayá A, Todolí J, et al. Thrombophilic risk factors and homocysteine levels in Behçet's disease in eastern Spain and their association with thrombotic events. Thromb Haemost 2006;95:618-624
39. Yalcindag FN, Batioglu F, Ozdemir O, et al. Soluble endothelial protein C receptor levels in Behçet patients with and without ocular involvement. Graefes Arch Clin Exp Ophthalmol 2008;246:1603-1608
40. Probst K, Fijnheer R, Rothova A. Endothelial cell activation and hypercoagulability in ocular Behçet's disease. Am J Ophthalmol 2004;137:850-857 (Pubitemid 38582037)